InnovAge Announces Financial Results for the Fiscal Third Quarter Ended March 31, 2025
- Revenue growth of 13.0% year-over-year to $218.1 million
- Adjusted EBITDA increased significantly to $10.8 million from $3.0 million
- Center-level Contribution Margin grew 19.9% to $40.7 million
- Census increased to 7,530 participants from 6,820 year-over-year
- Strong balance sheet with $101.8 million in cash and short-term investments
- Net loss widened to $11.1 million from $6.2 million year-over-year
- Loss per share doubled to $0.08 from $0.04
- Net loss margin deteriorated to 5.1% from 3.2%
- Departure of Chief Medical Officer Dr. Richard Feifer
- $77.3 million in debt on balance sheet
Insights
InnovAge shows revenue growth and operational improvements but widening losses create a mixed financial picture warranting cautious monitoring.
InnovAge delivered 13.0% revenue growth to
The company shows divergent operational metrics that create an intriguing financial narrative. Center-level Contribution Margin increased
The balance sheet remains solid with
The departure of the Chief Medical Officer adds a layer of uncertainty to the clinical leadership structure that bears watching, particularly given the company's focus on healthcare delivery.
InnovAge demonstrates PACE program growth and improved operational metrics despite widening net losses in a challenging senior care sector.
InnovAge continues expanding its footprint in the PACE (Program of All-inclusive Care for the Elderly) sector, with census growth to 7,530 participants representing significant market penetration in the specialized dual-eligible senior care segment. This demographic requires complex, coordinated care management - exactly what PACE programs are designed to deliver by keeping high-need seniors in their homes while reducing costly institutional care.
The company's improved Center-level Contribution Margin (
The CEO's emphasis on "disciplined cost management" and "effective medical expense control" highlights the company's focus on the delicate balance between appropriate care delivery and financial sustainability. This balancing act is essential in PACE programs, which must simultaneously optimize participant outcomes, generate savings for government payors (primarily Medicare and Medicaid), and maintain financial viability.
The departure of the Chief Medical Officer represents a transition in clinical leadership that will require careful management to maintain care quality and cost control standards across their 20 centers in six states.
DENVER, May 06, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced financial results for its fiscal third quarter ended March 31, 2025.
“Our third quarter results reflect continued strength in topline growth, disciplined cost management, and effective medical expense control,” said CEO Patrick Blair. “We are executing with greater consistency, and we are focused on building a PACE platform that delivers better outcomes for participants, generates meaningful savings for the healthcare system, and creates long-term value for our shareholders.”
Financial Results
| Three Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| in thousands, except percentages and per share amounts | |||||||
| Total revenues | $ | 218,142 | $ | 193,071 | |||
| Loss Before Income Taxes | (11,061 | ) | (6,408 | ) | |||
| Net Loss | (11,133 | ) | (6,184 | ) | |||
| Net Loss margin | (5.1 | )% | (3.2 | )% | |||
| Net Loss Attributable to InnovAge Holding Corp. | (11,378 | ) | (5,887 | ) | |||
| Net Loss per share - basic and diluted | $ | (0.08 | ) | $ | (0.04 | ) | |
| Center-level Contribution Margin(1) | $ | 40,747 | $ | 33,997 | |||
| Adjusted EBITDA(1) | $ | 10,792 | $ | 2,955 | |||
| Adjusted EBITDA margin(1) | 4.9 | % | 1.5 | % | |||
Fiscal Third Quarter 2025 Financial Performance
- Total revenue of
$218.1 million , increased approximately13.0% compared to$193.1 million in the third quarter of fiscal year 2024 - Loss Before Income Taxes of
$11.1 million increased approximately72.6% , compared to a Loss Before Income Taxes of$6.4 million in the third quarter of fiscal year 2024 - Loss Before Income Taxes as a percent of revenue was
5.1% , an increase of 1.8 percentage points, compared to Loss Before Income Tax as a percent of revenue of3.3% in the third quarter of fiscal year 2024 - Center-level Contribution Margin(1) of
$40.7 million , increased19.9% compared to$34.0 million in the third quarter of fiscal year 2024 - Center-level Contribution Margin(1) as a percent of revenue of
18.7% , increased 1.1 percentage points compared to17.6% in the third quarter of fiscal year 2024 - Net loss of
$11.1 million , compared to net loss of$6.2 million in the third quarter of fiscal year 2024 - Net loss margin of
5.1% , an increase of 1.9 percentage points compared to a net loss margin of3.2% in the third quarter of fiscal year 2024 - Net loss attributable to InnovAge Holding Corp. of
$11.4 million , or a loss of$0.08 per share, compared to net loss of$5.9 million , or a loss of$0.04 per share in the third quarter of fiscal year 2024 - Adjusted EBITDA(1) of
$10.8 million , an increase of$7.8 million compared to Adjusted EBITDA of$3.0 million in the third quarter of fiscal year 2024 - Adjusted EBITDA(1) margin of
4.9% , an increase of 3.4 percentage points compared to1.5% in the third quarter of fiscal year 2024 - Census of approximately 7,530 participants compared to 6,820 participants in the third quarter of fiscal year 2024
- Ended the third quarter of fiscal year 2025 with
$60.5 million in cash and cash equivalents plus$41.3 million in short-term investments, and$77.3 million in debt on the balance sheet, representing debt under the Company’s senior secured term loan, convertible term loan and finance leases
(1) Center-level Contribution Margin and Center-level Contribution Margin as a percentage of revenue, Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures. Effective for the year ended June 30, 2024 and going forward, the Company revised its calculation of Adjusted EBITDA and has recast the presentation for each of the three and nine months ended March 31, 2024 to conform to the current presentation. For more details and for a definition and reconciliation of these non-GAAP measures to the most closely comparable GAAP measures for the periods indicated, see “Note Regarding Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP and Non-GAAP Measures.”
Dr. Richard Feifer, InnovAge’s Chief Medical Officer, notified the Company of his intent to pursue other opportunities and departed effective April 25, 2025.
Full Fiscal Year 2025 Financial Guidance
Based on information as of today, May 6, 2025, InnovAge is confirming the following financial guidance.
| Low | High | ||||
| dollars in millions | |||||
| Census | 7,300 | 7,750 | |||
| Total Member Months(1) | 86,000 | 89,000 | |||
| Total revenues | $ | 815 | $ | 865 | |
| Adjusted EBITDA(2) | $ | 24 | $ | 31 | |
Expected results and estimates may be impacted by factors outside the Company’s control especially in light of the highly uncertain and rapidly evolving microeconomic environment and the volatility of the financial and capital markets. Accordingly, actual results may be materially different from this guidance. See “Forward-Looking Statements - Safe Harbor” herein.
(1) We define Total Member Months as the total number of participants as of period end multiplied by the number of months within a year in which each participant was enrolled in our program. Management believes this is a useful metric as it more precisely tracks the number of participants the Company serves throughout the year.
(2)Adjusted EBITDA is a non-GAAP measure. See “Note Regarding Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP and Non-GAAP Measures” for a definition of Adjusted EBITDA and a reconciliation to net loss, the most closely comparable GAAP measure. The Company is unable to provide guidance for net loss or a reconciliation of the Company’s Adjusted EBITDA guidance because it cannot provide a meaningful or accurate calculation or estimation of certain reconciling items without unreasonable effort. The Company’s inability to do so is due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including variations in effective tax rate, expenses to be incurred for acquisition activities and other one-time or exceptional items.
Conference Call
The Company will host a conference call this afternoon at 5:00 PM Eastern Time. A live audio webcast of the call will be available on the Company’s website, https://investor.innovage.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for a limited time. To access the call by phone, please go to this link (registration link), for dialing instructions and a unique access pin. We encourage participants to dial into the call fifteen minutes ahead of the scheduled start time.
About InnovAge
InnovAge is a market leader in managing the care of high-cost, frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care our participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers and government payors — “win.” As of March 31, 2025, InnovAge served approximately 7,530 participants across 20 centers in six states. https://www.innovage.com.
Investor Contact:
Ryan Kubota
rkubota@innovage.com
Media Contact:
Lara Hazenfield
lhazenfield@innovage.com
Forward-Looking Statements - Safe Harbor
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely,” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. Forward-looking statements may be identified by the fact that they do not relate strictly to historical or current facts. Examples of forward-looking statements include, among others, statements we make regarding quarterly or annual financial guidance; financial outlook, including future revenues and future earnings; the viability of our growth strategy including our ability or expectations to increase the number of participants we serve, to build and/or open de novo centers, or to identify and execute tuck-in acquisitions, joint ventures and strategic partnerships; the expected impact of government policies and the macroeconomic environment; our ability to control costs, mitigate the effects of elevated expenses, expand our payor capabilities, implement clinical value and operational value initiatives and strengthen enterprise functions; our expectations with respect to audits, post-sanction work, legal proceedings and government investigations and actions; relationships and discussions with regulatory agencies; our ability to effectively implement operational excellence as a provider across all our centers; reimbursement and regulatory developments; market developments; new services; integration activities; industry and market opportunity; and the effects of any of the foregoing on our future results of operations or financial conditions.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on currently available information and our current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control and may cause our actual results and financial condition to differ materially. Important factors that could cause our actual results and financial condition to differ materially include, among others, the following: (i) the viability of our growth strategy, including our ability to attract new participants and retain existing participants in new and existing centers and our ability to obtain licenses to open de novo centers including in Downey and Bakersfield, California; (ii) the impact on our business from ongoing macroeconomic related challenges, including labor shortages, labor competition and inflation, uncertainty surrounding the stability of economic conditions due to new and proposed tariffs and uncertainty in the global trade environment; (iii) inspections, reviews, audits, and investigations under the federal and state government programs, including any corrective action and adverse findings thereunder; (iv) the impact of state and federal efforts to reduce healthcare spending, including recent proposals to reduce the budget that funds Medicaid and Medicare; (v) legal proceedings, enforcement actions and litigation malpractice and privacy disputes, which are costly to defend; (vi) under our PACE contracts, we assume all of the risk that the cost of providing services will exceed our compensation; (vii) the dependence of our revenues upon a limited number of government payors; (viii) the risk that our submissions to government payors may contain inaccurate or unsupportable information, including regarding risk adjustment scores of participants, subjecting us to repayment obligations or penalties; and (ix) the impact on our business of renegotiation, non-renewal or termination of capitation agreements with government payors.
Forward-looking statements are based only on information currently available to us and speaks only as of the date on which it is made. Except as required by law, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. We advise you to not place undue reliance on forward-looking statements and to review our risk factors and other disclosures included in the reports we file or furnish with the Securities and Exchange Commission, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
Note Regarding Use of Non-GAAP Financial Measures
In addition to reporting financial information in accordance with generally accepted accounting principles (“GAAP”), the Company is also reporting Center-level Contribution Margin, Center-level Contribution Margin as a percentage of revenue, Adjusted EBITDA and Adjusted EBITDA margin, which are non-GAAP financial measures. These non-GAAP measures are supplemental measures of operating performance monitored by management that are not defined under GAAP and that do not represent, and should not be considered as, an alternative to net income (loss) before income taxes, net income (loss) before income taxes margin, net income (loss) and net income (loss) margin, as applicable, as determined by GAAP. We believe that these non-GAAP measures are appropriate measures of operating performance because the metrics eliminate the impact of certain expenses that, in the case of Adjusted EBITDA, do not relate to our ongoing business performance, allowing us to more effectively evaluate our core operating performance and trends from period to period. We believe that these non-GAAP measures help investors and analysts in comparing our results across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation from, or as a substitute for, the analysis of other GAAP financial measures, including net income (loss) before taxes, net income (loss) before taxes margin, net income (loss), and net income (loss) margin.
The Company’s management uses Center-level Contribution Margin as the measure for assessing performance of its operating segments. For purpose of evaluating Center-level Contribution Margin on a center-by-center basis, we do not allocate our sales and marketing expense or corporate, general and administrative expenses across our centers. We define Center-level Contribution Margin as total revenues less external provider costs and cost of care, excluding depreciation and amortization, which includes all medical and pharmacy costs.
In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed to imply that our future results will be unaffected by the types of items excluded from the calculation of Adjusted EBITDA. Our use of the term Adjusted EBITDA varies from others in our industry. We define Adjusted EBITDA as net loss adjusted for interest expense, net, other investment income, depreciation and amortization, and provision (benefit) for income tax as well as addbacks for non-recurring expenses or exceptional items, including charges relating to management equity compensation, litigation costs and settlement, M&A diligence, transaction and integration, business optimization, electronic medical record (“EMR”) implementation, impairment of right-of-use (“ROU”) asset and construction in progress and loss on minority equity interest. Adjusted EBITDA margin is Adjusted EBITDA expressed as a percentage of our total revenue. Effective for the year ended June 30, 2024, and going forward, the Company revised its calculation of Adjusted EBITDA to no longer exclude de novo center development costs and to reflect the impact of other investment income. The presentation for the three and nine months ended March 31, 2024 has been recast to conform to the current presentation. For a full reconciliation of Center-level Contribution Margin and Adjusted EBITDA to the most closely comparable GAAP financial measures, please see the attachment to this earnings release.
Schedule 1
InnovAge
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT NUMBER OF SHARES) (UNAUDITED)
| March 31, 2025 | June 30, 2024 | ||||||
| Assets | |||||||
| Current Assets | |||||||
| Cash and cash equivalents | $ | 60,454 | $ | 56,946 | |||
| Short-term investments | 41,279 | 45,833 | |||||
| Restricted cash | 12 | 14 | |||||
| Accounts receivable, net of allowance ($— – March 31, 2025 and | 44,400 | 48,106 | |||||
| Prepaid expenses | 26,714 | 18,919 | |||||
| Income tax receivable | 3,324 | 3,324 | |||||
| Total current assets | 176,183 | 173,142 | |||||
| Noncurrent Assets | |||||||
| Property and equipment, net | 177,502 | 193,022 | |||||
| Operating lease assets | 25,229 | 28,416 | |||||
| Investments | 2,645 | 2,645 | |||||
| Deposits and other | 9,001 | 5,949 | |||||
| Goodwill | 142,046 | 139,949 | |||||
| Other intangible assets, net | 4,042 | 4,538 | |||||
| Total noncurrent assets | 360,465 | 374,519 | |||||
| Total assets | $ | 536,648 | $ | 547,661 | |||
| Liabilities and Stockholders' Equity | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued expenses | $ | 75,175 | $ | 55,459 | |||
| Reported and estimated claims | 61,682 | 55,404 | |||||
| Due to Medicaid and Medicare | 17,321 | 15,197 | |||||
| Current portion of long-term debt | 60,983 | 3,795 | |||||
| Current portion of finance lease obligations | 5,397 | 4,599 | |||||
| Current portion of operating lease obligations | 4,761 | 4,145 | |||||
| Total current liabilities | 225,319 | 138,599 | |||||
| Noncurrent Liabilities | |||||||
| Deferred tax liability, net | 7,969 | 7,460 | |||||
| Finance lease obligations | 8,797 | 12,743 | |||||
| Operating lease obligations | 23,685 | 26,275 | |||||
| Other noncurrent liabilities | 1,408 | 1,298 | |||||
| Long-term debt, net of debt issuance costs | 1,765 | 61,478 | |||||
| Total liabilities | 268,943 | 247,853 | |||||
| Commitments and Contingencies | |||||||
| Redeemable Noncontrolling Interests | 22,100 | 22,200 | |||||
| Stockholders’ Equity | |||||||
| Common stock, | 136 | 136 | |||||
| Treasury stock at cost, 1,361,159 and 36,559 shares as of March 31, 2025 and June 30, 2024, respectively | (7,203 | ) | (179 | ) | |||
| Additional paid-in capital | 342,870 | 337,615 | |||||
| Retained deficit | (97,839 | ) | (68,311 | ) | |||
| Total InnovAge Holding Corp. | 237,964 | 269,261 | |||||
| Noncontrolling interests | 7,641 | 8,347 | |||||
| Total stockholders’ equity | 245,605 | 277,608 | |||||
| Total liabilities and stockholders’ equity | $ | 536,648 | $ | 547,661 | |||
Schedule 2
InnovAge
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE DATA) (UNAUDITED)
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenues | |||||||||||||||
| Capitation revenue | $ | 217,819 | $ | 192,756 | $ | 631,293 | $ | 563,490 | |||||||
| Other service revenue | 323 | 315 | 989 | 964 | |||||||||||
| Total revenues | 218,142 | 193,071 | 632,282 | 564,454 | |||||||||||
| Expenses | |||||||||||||||
| External provider costs | 107,896 | 99,996 | 322,983 | 300,319 | |||||||||||
| Cost of care, excluding depreciation and amortization | 69,499 | 59,078 | 196,947 | 168,649 | |||||||||||
| Sales and marketing | 6,922 | 7,179 | 21,117 | 18,416 | |||||||||||
| Corporate, general and administrative | 38,597 | 27,549 | 94,235 | 81,746 | |||||||||||
| Depreciation and amortization | 5,386 | 5,062 | 16,116 | 13,621 | |||||||||||
| Impairment of right-of-use asset and construction in progress | — | — | 8,495 | — | |||||||||||
| Total expenses | 228,300 | 198,864 | 659,893 | 582,751 | |||||||||||
| Operating Loss | (10,158 | ) | (5,793 | ) | (27,611 | ) | (18,297 | ) | |||||||
| Other Income (Expense) | |||||||||||||||
| Interest expense, net | (1,160 | ) | (1,022 | ) | (3,719 | ) | (2,619 | ) | |||||||
| Other income | 257 | 525 | 1,489 | 2,043 | |||||||||||
| Gain (loss) on equity method investment | — | (118 | ) | 16 | (2,000 | ) | |||||||||
| Total other expense | (903 | ) | (615 | ) | (2,214 | ) | (2,576 | ) | |||||||
| Loss Before Income Taxes | (11,061 | ) | (6,408 | ) | (29,825 | ) | (20,873 | ) | |||||||
| Provision (Benefit) for Income Taxes | 72 | (224 | ) | 509 | 94 | ||||||||||
| Net Loss | (11,133 | ) | (6,184 | ) | (30,334 | ) | (20,967 | ) | |||||||
| Less: net income (loss) attributable to noncontrolling interests | 245 | (297 | ) | (806 | ) | (1,329 | ) | ||||||||
| Net Loss Attributable to InnovAge Holding Corp. | $ | (11,378 | ) | $ | (5,887 | ) | $ | (29,528 | ) | $ | (19,638 | ) | |||
| Weighted-average number of common shares outstanding - basic | 135,200,314 | 135,908,256 | 135,471,907 | 135,861,922 | |||||||||||
| Weighted-average number of common shares outstanding - diluted | 135,200,314 | 135,908,256 | 135,471,907 | 135,861,922 | |||||||||||
| Net loss per share - basic | $ | (0.08 | ) | $ | (0.04 | ) | $ | (0.22 | ) | $ | (0.14 | ) | |||
| Net loss per share - diluted | $ | (0.08 | ) | $ | (0.04 | ) | $ | (0.22 | ) | $ | (0.14 | ) | |||
Schedule 3
InnovAge
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS) (UNAUDITED)
| For the Nine Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Operating Activities | |||||||
| Net loss | $ | (30,334 | ) | $ | (20,967 | ) | |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities | |||||||
| Loss (gain) on disposal of assets | 260 | (14 | ) | ||||
| Provision for uncollectible accounts | 524 | 5,252 | |||||
| Depreciation and amortization | 16,116 | 13,621 | |||||
| Operating lease rentals | 4,738 | 3,831 | |||||
| Impairment of right-of-use asset and construction in progress | 8,495 | — | |||||
| Amortization of deferred financing costs | 322 | 322 | |||||
| Stock-based compensation | 6,069 | 5,140 | |||||
| Loss on minority equity interest investment | — | 2,000 | |||||
| Deferred income taxes | 509 | (78 | ) | ||||
| Other, net | 1,173 | 302 | |||||
| Changes in operating assets and liabilities, net of acquisitions | |||||||
| Accounts receivable, net | 3,183 | (16,802 | ) | ||||
| Prepaid expenses and other current assets | (6,275 | ) | 4,382 | ||||
| Income tax receivable | — | (3,068 | ) | ||||
| Deposits and other | (4,471 | ) | (2,350 | ) | |||
| Accounts payable and accrued expenses | 20,062 | (5,402 | ) | ||||
| Reported and estimated claims | 6,278 | 6,171 | |||||
| Due to Medicaid and Medicare | 2,125 | 2,270 | |||||
| Income taxes payable | — | (1,212 | ) | ||||
| Operating lease liabilities | (4,909 | ) | (4,054 | ) | |||
| Deferred revenue | — | (28,115 | ) | ||||
| Net cash provided by (used in) operating activities | 23,865 | (38,771 | ) | ||||
| Investing Activities | |||||||
| Purchases of property and equipment | (6,442 | ) | (4,609 | ) | |||
| Purchases of short-term investments | (1,610 | ) | (1,782 | ) | |||
| Proceeds from sale of short-term investments | 6,300 | 3,000 | |||||
| Acquisition of business | (4,774 | ) | (23,916 | ) | |||
| Net cash used in investing activities | (6,526 | ) | (27,307 | ) | |||
| Financing Activities | |||||||
| Payments for finance lease obligations | (3,147 | ) | (3,581 | ) | |||
| Principal payments on long-term debt | (2,848 | ) | (2,846 | ) | |||
| Repurchase of equity securities | (7,024 | ) | — | ||||
| Taxes paid related to net settlements of stock-based compensation awards | (814 | ) | (651 | ) | |||
| Net cash used in financing activities | (13,833 | ) | (7,078 | ) | |||
| INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS & RESTRICTED CASH | 3,506 | (73,156 | ) | ||||
| CASH, CASH EQUIVALENTS & RESTRICTED CASH, BEGINNING OF PERIOD | 56,960 | 127,265 | |||||
| CASH, CASH EQUIVALENTS & RESTRICTED CASH, END OF PERIOD | $ | 60,466 | $ | 54,109 | |||
| Supplemental Cash Flows Information | |||||||
| Interest paid | $ | 3,413 | $ | 2,894 | |||
| Income taxes paid | $ | 1 | $ | 4,452 | |||
| Property and equipment included in accounts payable | $ | 52 | $ | 432 | |||
| Property and equipment purchased under finance leases | $ | — | $ | 108 | |||
Schedule 4
InnovAge
RECONCILIATION OF GAAP AND NON-GAAP MEASURES
(IN THOUSANDS) (UNAUDITED)
Adjusted EBITDA
| Three months ended March 31, | Nine months ended March 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net loss | $ | (11,133 | ) | $ | (6,184 | ) | $ | (30,334 | ) | $ | (20,967 | ) | |||
| Interest expense, net | 1,160 | 1,022 | 3,719 | 2,619 | |||||||||||
| Other investment income(a) | (503 | ) | (590 | ) | (1,750 | ) | (1,788 | ) | |||||||
| Depreciation and amortization | 5,386 | 5,062 | 16,116 | 13,621 | |||||||||||
| Provision for income tax | 72 | (224 | ) | 509 | 94 | ||||||||||
| Stock-based compensation | 2,035 | 1,551 | 6,069 | 5,140 | |||||||||||
| Litigation costs and settlement(b) | 13,277 | 897 | 17,741 | 2,802 | |||||||||||
| M&A diligence, transaction and integration(c) | 202 | 210 | 1,582 | 384 | |||||||||||
| Business optimization(d) | 152 | 738 | 845 | 3,672 | |||||||||||
| EMR implementation(e) | — | 355 | — | 3,659 | |||||||||||
| Asset impairments and loss on sale of assets(f) | 144 | — | 8,639 | — | |||||||||||
| Loss on minority equity interest(g) | — | 118 | — | 2,000 | |||||||||||
| Adjusted EBITDA | $ | 10,792 | $ | 2,955 | $ | 23,136 | $ | 11,236 | |||||||
| Net loss margin | (6.4 | )% | (2.0 | )% | (4.6 | )% | (4.0 | )% | |||||||
| Adjusted EBITDA margin | 2.8 | % | 3.7 | % | 3.0 | % | 2.2 | % | |||||||
| _______________________ | |
| (a) | Reflects investment income related to short-term investments included in our consolidated statement of operations. Effective for the year ended June 30, 2024 and going forward, the Company revised the calculation for Adjusted EBITDA to reflect the impact of investment income. The presentation for the three and nine months ended March 31, 2024 has been recast to reflect the impact of other investment income. |
| (b) | Reflects charges/(credits) related to litigation by stockholders, litigation related to de novo center, and civil investigative demands. Refer to Note 9, "Commitments and Contingencies" to our condensed consolidated financial statements for more information regarding litigation by stockholders and civil investigative demands. Costs reflected consist of litigation costs considered one-time in nature and outside of the ordinary course of business based on the following considerations which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) complexity of the case, (iii) nature of the remedies sought, (iv) litigation posture of the Company, (v) counterparty involved, and (vi) the Company's overall litigation strategy. For the three and nine months ended March 31, 2025, includes |
| (c) | Reflects charges related to M&A transaction and integrations. The presentation for the three and nine months ended March 31, 2024 has been recast to no longer exclude de novo center development costs. |
| (d) | Reflects charges related to business optimization initiatives. Such charges relate to one-time investments in projects designed to enhance our technology and compliance systems and improve and support the efficiency and effectiveness of our operations. For the three months ended March 31, 2025, this primarily includes costs related to other non-recurring projects aimed at reducing costs and improving efficiencies. For the nine months ended March 31, 2025, this includes (i) |
| (e) | Reflects non-recurring expenses relating to the implementation of a new EMR vendor. |
| (f) | Reflects (i) impairment charges related to ROU asset and construction in progress related to halting developments to a previously planned de novo center in Louisville, Kentucky that the Company is no longer pursuing and (ii) loss on sale of center equipment that was originally purchased for the center in Louisville, Kentucky. |
| (g) | Reflects impairment charges related to our minority equity interest in Jetdoc, Inc. |
| Three months ended December 31, | |||
| 2024 | |||
| Net loss | $ | (13,491 | ) |
| Interest expense, net | 760 | ||
| Other investment income | 141 | ||
| Depreciation and amortization | 5,319 | ||
| Provision for income tax | 34 | ||
| Stock-based compensation | 1,873 | ||
| Litigation costs and settlement(a) | 1,405 | ||
| M&A diligence, transaction and integration | 1,275 | ||
| Business optimization(b) | 58 | ||
| Impairment of right-of-use asset and construction in progress(c) | 8,495 | ||
| Adjusted EBITDA | $ | 5,869 | |
| Net loss margin | (5.1 | )% | |
| Adjusted EBITDA margin | 4.9 | % | |
| _______________________ | |
| (a) | Reflects charges/(credits) related to litigation by stockholders, litigation related to de novo center, and civil investigative demands. Refer to Note 9, “Commitments and Contingencies” to our condensed consolidated financial statements contained in our Quarterly Report on Form 10-Q for more information regarding litigation by stockholders and civil investigative demands. Costs reflected consist of litigation costs considered one-time in nature and outside of the ordinary course of business based on the following considerations which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) complexity of the case, (iii) nature of the remedies sought, (iv) litigation posture of the Company, (v) counterparty involved, and (vi) the Company's overall litigation strategy. |
| (b) | Reflects charges related to business optimization initiatives. Such charges relate to one-time investments in projects designed to enhance our technology and compliance systems and improve and support the efficiency and effectiveness of our operations. For the three months ended December 31, 2024, this primarily includes costs related to other non-recurring projects aimed at reducing costs and improving efficiencies. |
| (c) | Reflects impairment charges related to ROU asset and construction in progress related to halting developments to a previously planned de novo center in Louisville, Kentucky that the Company is no longer pursuing. |
Center-Level Contribution Margin
| Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | ||||||||||||||||||||||
| (In thousands) | PACE | All other(a) | Totals | PACE | All other(a) | Totals | |||||||||||||||||
| Capitation revenue | $ | 217,819 | $ | — | $ | 217,819 | $ | 192,756 | $ | — | $ | 192,756 | |||||||||||
| Other service revenue | 79 | 244 | 323 | 78 | 237 | 315 | |||||||||||||||||
| Total revenues | 217,898 | 244 | 218,142 | 192,834 | 237 | 193,071 | |||||||||||||||||
| External provider costs | 107,896 | — | 107,896 | 99,996 | — | 99,996 | |||||||||||||||||
| Cost of care, excluding depreciation and amortization | 69,372 | 127 | 69,499 | 58,959 | 119 | 59,078 | |||||||||||||||||
| Center-Level Contribution Margin | 40,630 | 117 | 40,747 | 33,879 | 118 | 33,997 | |||||||||||||||||
| Overhead costs(b) | 45,519 | — | 45,519 | 34,727 | 1 | 34,728 | |||||||||||||||||
| Depreciation and amortization | 5,279 | 107 | 5,386 | 4,929 | 133 | 5,062 | |||||||||||||||||
| Interest expense, net | (1,117 | ) | (43 | ) | (1,160 | ) | (978 | ) | (44 | ) | (1,022 | ) | |||||||||||
| Other income | 257 | — | 257 | 525 | — | 525 | |||||||||||||||||
| Gain (loss) on equity method investment | — | — | — | (118 | ) | — | (118 | ) | |||||||||||||||
| Loss Before Income Taxes | $ | (11,028 | ) | $ | (33 | ) | $ | (11,061 | ) | $ | (6,348 | ) | $ | (60 | ) | $ | (6,408 | ) | |||||
| Loss Before Income Taxes as a % of revenue | (5.1 | )% | (3.3 | )% | |||||||||||||||||||
| Center- Level Contribution Margin as a % of revenue | 18.7 | % | 17.6 | % | |||||||||||||||||||
| December 31, 2024 | |||||||||||
| (In thousands) | PACE | All other(a) | Totals | ||||||||
| Capitation revenue | $ | 208,674 | $ | — | $ | 208,674 | |||||
| Other service revenue | 77 | 248 | 325 | ||||||||
| Total revenues | 208,751 | 248 | 208,999 | ||||||||
| External provider costs | 107,873 | — | 107,873 | ||||||||
| Cost of care, excluding depreciation and amortization | 63,916 | 145 | 64,061 | ||||||||
| Center-Level Contribution Margin | 36,962 | 103 | 37,065 | ||||||||
| Overhead costs(b) | 35,807 | — | 35,807 | ||||||||
| Depreciation and amortization | 5,204 | 115 | 5,319 | ||||||||
| Impairment of right-of-use asset and construction in progress | 8,495 | — | 8,495 | ||||||||
| Interest expense, net | (716 | ) | (44 | ) | (760 | ) | |||||
| Other income (expense) | (157 | ) | — | (157 | ) | ||||||
| Gain (loss) on equity method investment | 16 | — | 16 | ||||||||
| Loss Before Income Taxes | $ | (13,401 | ) | $ | (56 | ) | $ | (13,457 | ) | ||
| Loss Before Income Taxes as a % of revenue | (6.4 | )% | |||||||||
| Center- Level Contribution Margin as a % of revenue | 17.7 | % | |||||||||
| _______________________ | |
| (a) | Center-level Contribution Margin from segments below the quantitative thresholds are primarily attributable to the Senior Housing operating segment of the Company. This segment has never met any of the quantitative thresholds for determining reportable segments. |
| (b) | Overhead consists of the Sales and marketing and Corporate, general and administrative financial statement line items. |
This press release was published by a CLEAR® Verified individual.
FAQ
What were InnovAge's (INNV) Q3 2025 earnings results?
How much did InnovAge's (INNV) Adjusted EBITDA improve in Q3 2025?
What is InnovAge's (INNV) revenue guidance for fiscal year 2025?
How many participants does InnovAge (INNV) serve as of Q3 2025?
What is InnovAge's (INNV) current cash position?
